These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36171144)

  • 1. Clinical characteristics and efficacy of pioglitazone in a Japanese patient with familial partial lipodystrophy due to peroxisome proliferator-activated receptor γ gene mutation.
    Iizaka T; Kodama E; Mikura K; Iida T; Imai H; Hashizume M; Kigawa Y; Sugisawa C; Tadokoro R; Endo K; Otsuka F; Isoda M; Ebihara K; Ishibashi S; Nagasaka S
    Endocr J; 2023 Jan; 70(1):69-76. PubMed ID: 36171144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of non-obese diabetic patients with marked insulin resistance identifies a novel familial partial lipodystrophy-associated PPARγ mutation (Y151C).
    Visser ME; Kropman E; Kranendonk ME; Koppen A; Hamers N; Stroes ES; Kalkhoven E; Monajemi H
    Diabetologia; 2011 Jul; 54(7):1639-44. PubMed ID: 21479595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.
    Demir T; Onay H; Savage DB; Temeloglu E; Uzum AK; Kadioglu P; Altay C; Ozen S; Demir L; Cavdar U; Akinci B
    Diabet Med; 2016 Oct; 33(10):1445-50. PubMed ID: 26756202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and efficacy of pioglitazone in a Japanese diabetic patient with an unusual type of familial partial lipodystrophy.
    Iwanishi M; Ebihara K; Kusakabe T; Chen W; Ito J; Masuzaki H; Hosoda K; Nakao K
    Metabolism; 2009 Dec; 58(12):1681-7. PubMed ID: 19793595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics, Phenotype of Lipodystrophy and a Genetic Analysis of Six Diabetic Japanese Women with Familial Partial Lipodystrophy in a Diabetic Outpatient Clinic.
    Iwanishi M; Ito-Kobayashi J; Washiyama M; Kusakabe T; Ebihara K
    Intern Med; 2018 Aug; 57(16):2301-2313. PubMed ID: 29607946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance.
    Lambadiari V; Kountouri A; Maratou E; Liatis S; Dimitriadis GD; Karpe F
    Front Endocrinol (Lausanne); 2021; 12():684182. PubMed ID: 34168618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-gamma C190S mutation causes partial lipodystrophy.
    Lüdtke A; Buettner J; Wu W; Muchir A; Schroeter A; Zinn-Justin S; Spuler S; Schmidt HH; Worman HJ
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2248-55. PubMed ID: 17356052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: A New Peroxisome Proliferator-Activated Receptor Gamma Mutation Causes Familial Partial Lipodystrophy Type 3 in a Chinese Patient.
    Chen X; Ma Z; Chen P; Song X; Li W; Yu X; Xie J
    Front Endocrinol (Lausanne); 2022; 13():830708. PubMed ID: 35422762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
    Lüdtke A; Buettner J; Schmidt HH; Worman HJ
    J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical presentations, metabolic abnormalities and end-organ complications in patients with familial partial lipodystrophy.
    Akinci B; Onay H; Demir T; Savas-Erdeve Ş; Gen R; Simsir IY; Keskin FE; Erturk MS; Uzum AK; Yaylali GF; Ozdemir NK; Atik T; Ozen S; Yurekli BS; Apaydin T; Altay C; Akinci G; Demir L; Comlekci A; Secil M; Oral EA
    Metabolism; 2017 Jul; 72():109-119. PubMed ID: 28641778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Familial partial lipodystrophy phenotype resulting from a single-base mutation in deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma.
    Monajemi H; Zhang L; Li G; Jeninga EH; Cao H; Maas M; Brouwer CB; Kalkhoven E; Stroes E; Hegele RA; Leff T
    J Clin Endocrinol Metab; 2007 May; 92(5):1606-12. PubMed ID: 17299075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3.
    Miehle K; Porrmann J; Mitter D; Stumvoll M; Glaser C; Fasshauer M; Hoffmann K
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):141-8. PubMed ID: 26119484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acid metabolism in patients with PPARgamma mutations.
    Tan GD; Savage DB; Fielding BA; Collins J; Hodson L; Humphreys SM; O'Rahilly S; Chatterjee K; Frayn KN; Karpe F
    J Clin Endocrinol Metab; 2008 Nov; 93(11):4462-70. PubMed ID: 18713822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
    Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
    Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inguinal Fat Compensates Whole Body Metabolic Functionality in Partially Lipodystrophic Mice with Reduced PPARγ Expression.
    Chang CS; Yu SS; Ho LC; Chao SH; Chou TY; Shao AN; Kao LZ; Chang CY; Chen YH; Wu MS; Tsai PJ; Maeda N; Tsai YS
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel heterozygous mutation in peroxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy.
    Agarwal AK; Garg A
    J Clin Endocrinol Metab; 2002 Jan; 87(1):408-11. PubMed ID: 11788685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial partial lipodystrophy associated with the heterozygous LMNA mutation 1445G>A (Arg482Gln) in a Polish family.
    Drac H; Madej-Pilarczyk A; Gospodarczyk-Szot K; Gaweł M; Kwieciński H; Hausmanowa-Petrusewicz I
    Neurol Neurochir Pol; 2010; 44(3):291-6. PubMed ID: 20625965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
    Sleilati GG; Leff T; Bonnett JW; Hegele RA
    Endocr Pract; 2007 Oct; 13(6):656-61. PubMed ID: 17954424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fitting the pieces of the puzzle together: a case report of the Dunnigan-type of familial partial lipodystrophy in the adolescent girl.
    Krawiec P; Mełges B; Pac-Kożuchowska E; Mroczkowska-Juchkiewicz A; Czerska K
    BMC Pediatr; 2016 Mar; 16():38. PubMed ID: 26976018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new type of familial partial lipodystrophy: distinctive fat distribution and proteinuria.
    Yurekli B; Ozdemir Kutbay N; Altay C; Unlu SM; Sen S; Onay H; Atik T; Akinci B
    Endocr Res; 2018 Nov; 43(4):258-263. PubMed ID: 29733702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.